Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

172 та иш

Иш: Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

  1. Disorders of cancer metabolism: The therapeutic potential of cannabinoids

    Dingya Sun, Xin Li, Shengdan Nie +2

    Шарҳ мақола20229 иқтибос
    ABI

  2. Tumor Cell-Targeting and Tumor Microenvironment–Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer

    Ying Wang, Yiyan Xu, Jiayu Song +8

    Мақола20248 иқтибос
    ABI

  3. <scp>CHB</scp> patients with <scp>rtA181T</scp>‐mutated <scp>HBV</scp> infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes

    Qiqi Ning, Tongwang Yang, Xianghua Guo +8

    Мақола20238 иқтибос
    ABI

  4. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Шарҳ мақола20236 иқтибос
    ABI

  5. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Мақола20236 иқтибос
    ABI

  6. Exploring treatment options in cancer: tumor treatment strategies

    Beilei Liu, Hongyu Zhou, Licheng Tan +2

    Шарҳ мақола20245 иқтибос
    ABI

  7. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder

    Yutao Lou, Mengting Cheng, Qin Cao +7

    Мақола20235 иқтибос
    ABI

  8. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy

    Zhibin Wang, Xiu Zhang, Chao Fang +4

    Шарҳ мақола20244 иқтибос
    ABI

  9. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)

    Fei Li, Jiaqi Tian, Lin Zhang +2

    Шарҳ мақола20244 иқтибос
    ABI

  10. Alantolactone: structural enhancements and therapeutic insights for cancer and inflammation

    Muzaffar Kayumov, Fotima A. Sobirova, Okhunjon Khasanov +3

    Шарҳ мақолаSesquiterpenes and Asteraceae StudiesNatural Product Research20253 иқтибос
    ABI

  11. Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local–national perspective

    Feng Hu, Huijie Yang, Liping Qiu +6

    Мақола20253 иқтибос
    ABI

  12. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)

    Chang Hoon Ji, Min Ju Lee, Hee Yeon Kim +5

    Бошқа20223 иқтибос
    ABI

  13. Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs

    Madhukiran R. Dhondale, Pradip Thakor, Amritha G. Nambiar +4

    Шарҳ мақола20232 иқтибос
    ABI

  14. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

    Jill Hallin, Lars D. Engstrom, Lauren Hargis +31

    Мақола20192 иқтибос
    ABI

  15. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

    Longchuan Bai, Haibin Zhou, Renqi Xu +15

    Мақола20192 иқтибос
    ABI

  16. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

    Ian Churcher

    Шарҳ мақола20172 иқтибос
    ABI

  17. AUTACs: Cargo-Specific Degraders Using Selective Autophagy

    Daiki Takahashi, Jun Moriyama, Tomoe Y. Nakamura +6

    Мақола20192 иқтибос
    ABI

  18. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

    Xin Lin, Hua Xiang, Guoshun Luo

    Шарҳ мақола20202 иқтибос
    ABI

  19. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

    Adam D. Cotton, Duy Nguyen, Josef A. Gramespacher +2

    Мақола20212 иқтибос
    ABI

  20. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

    Heng Zhang, Yu Han, Yuanfan Yang +7

    Мақола20212 иқтибос
    ABI

  21. PROTAC targeted protein degraders: the past is prologue

    Miklós Békés, David R. Langley, Craig M. Crews

    Шарҳ мақола20222 иқтибос
    ABI

  22. Proteolysis-targeting chimeras (PROTACs) in cancer therapy

    Xinyi Li, Wenchen Pu, Qingquan Zheng +3

    Мақола20222 иқтибос
    ABI

  23. Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases

    Fengzhi Li, Ieman Aljahdali, Xiang Ling

    Шарҳ мақола20222 иқтибос
    ABI

  24. Targeted Protein Degradation via Lysosomes

    Rishi R. Paudel, Dong Lu, Sandipan Chowdhury +2

    Шарҳ мақола20222 иқтибос
    ABI

  25. Targeted Protein Degradation: Clinical Advances in the Field of Oncology

    Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova +1

    Шарҳ мақола20222 иқтибос
    ABI